Valuation: Armata Pharmaceuticals, Inc.

Market Cap 239M 209M 193M 181M 339M 22.51B 346M 2.32B 897M 11.12B 896M 876M 38.58B P/E 2026 *
-1.71x
P/E 2027 * -4.85x
Enterprise Value 239M 209M 193M 181M 339M 22.51B 346M 2.32B 897M 11.12B 896M 876M 38.58B EV / Sales 2026 *
108x
EV / Sales 2027 * 86.8x
Free-Float
31.45%
Yield 2026 *
-
Yield 2027 * -
05-13 Armata pharmaceuticals announces first quarter 2026 results and provides corporate update RE
05-13 Armata Pharmaceuticals, Inc. Enters into A Secured Credit Agreement with Innoviva Strategic Opportunities LLC CI
05-13 Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Armata Pharmaceuticals Inc Secures FDA Fast Track Designation For AP-SA02 CI
04-27 Armata Pharmaceuticals, Inc. Appoints Daniel B. Gilmer, Ph.D. to Its Board of Directors, Effective April 24, 2026 CI
04-26 Zambon Spa, Insmed Incorporated, Novabiotics, Haisco Pharmaceutical Group, Armata Pharmaceuticals, Chiesi Farmaceutici, Csl Behring, and Others Announces Brensocatib Clinical Progress and Approvals for Non-Cystic Fibrosis Bronchiectasis CI
03-25 Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-24 Armata Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt CI
03-19 Armata Pharmaceuticals delays announcement of fourth quarter and full-year 2025 results and provides corporate update RE
02-23 Armata Says FDA Grants Qualified Infectious Disease Product Designation to Complicated Bacteremia Treatment MT
02-23 Armata Pharmaceuticals receives FDA qualified infectious disease product designation RE
02-23 Armata Pharmaceuticals, Inc. Receives FDA Qualified Infectious Disease Product Designation for AP-SA02 CI
01-26 Armata Pharmaceuticals, Inc. Enters into Amendments to Four Existing Credit Agreements CI
1 day+13.85%
1 week+4.52%
Current month-9.42%
1 month-11.48%
3 months-14.05%
6 months+15.44%
Current year+17.83%
1 week 6.38
Extreme 6.38
7.63
1 month 6.37
Extreme 6.3701
8.46
Current year 5.66
Extreme 5.66
14.98
1 year 1.85
Extreme 1.85
16.34
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 2023-07-10
Director of Finance/CFO 42 2024-08-15
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 2019-05-08
Director/Board Member 68 2019-10-09
Director/Board Member 66 2020-02-11
Date Insider Type Main position Quantity % Market Cap.
04-23Free

Director

51,280 0.1400%
03-13Tax

Public Communications Manager

1,030 0.0028%
03-13Tax

Chief Executive Officer

4,919 0.0135%
Change 5-day change 1-year change 3-year change Capi.($)
+13.85%+4.52%+271.86%+440.15% 239M
+0.33%+2.83%+62.37%+115.97% 55.35B
+0.82%+15.05%+74.28%+86.70% 51.92B
+1.36%+0.36%-12.96%-14.86% 22.76B
-1.04%+7.91%-1.40%+417.94% 22.64B
-0.18%+7.20%+28.56%-12.48% 17.36B
-1.10%+4.61%+29.38%-34.99% 16.1B
-3.35%+8.96%+135.18%+294.38% 13.96B
+2.89%+5.51%+25.82%+175.78% 13.38B
+1.31%+0.53%+27.21% - 12.27B
Average +1.49%+4.57%+64.03%+163.18% 22.6B
Weighted average by Cap. +0.26%+5.29%+46.83%+120.88%

Financials

2026 *2027 *
Net sales 2.2M 1.93M 1.78M 1.66M 3.12M 208M 3.19M 21.37M 8.27M 103M 8.26M 8.08M 356M 2.75M 2.41M 2.22M 2.08M 3.9M 259M 3.98M 26.71M 10.34M 128M 10.33M 10.1M 445M
Net income -172M -151M -139M -130M -244M -16.22B -249M -1.67B -646M -8.01B -645M -631M -27.79B -66.35M -58.18M -53.62M -50.2M -94.14M -6.26B -96.09M -645M -249M -3.09B -249M -244M -10.73B
Net Debt - -
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
26-06-26 US$7.400 +13.85% 1,561,283
26-06-25 US$6.500 -11.56% 420,148
26-06-24 US$7.350 +4.85% 356,136
26-06-23 US$7.010 +2.04% 141,263
26-06-22 US$6.870 -2.97% 34,217
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.500USD
Average target price
17.50USD
Spread / Average Target
+169.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARMP Stock